A Quarter of a Century Later: What is Dofetilide’s Clinical Role Today?

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post–myocardial infarction patients and those with heart failure. This is a review of postmarket data, including real-world efficacy and safety in a variety of populations. Dofetilide has been used off-label with success in patients with paroxysmal atrial fibrillation and atrial flutter, as well as atrial tachycardia and ventricular tachycardia. The real-world acute conversion rate of atrial fibrillation and atrial flutter is higher than that reported in clinical trials. Dofetilide has an acceptable safety profile when initiated (or reloaded) under hospital monitoring and dosed according to creatinine clearance. Dofetilide is well tolerated and a good choice for patients with acceptable renal function and a normal QT interval, especially if atrioventricular nodal blockade needs to be avoided.

Original languageEnglish (US)
Pages (from-to)3-10
Number of pages8
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Atrial Flutter
Atrial Fibrillation
Safety
United States Food and Drug Administration
Ventricular Tachycardia
Tachycardia
Infarction
Cardiac Arrhythmias
Creatinine
Heart Failure
Maintenance
Clinical Trials
Kidney
Mortality
dofetilide
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

@article{9a0bac8a58b0484fb8f8efe7ad852c64,
title = "A Quarter of a Century Later: What is Dofetilide’s Clinical Role Today?",
abstract = "Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post–myocardial infarction patients and those with heart failure. This is a review of postmarket data, including real-world efficacy and safety in a variety of populations. Dofetilide has been used off-label with success in patients with paroxysmal atrial fibrillation and atrial flutter, as well as atrial tachycardia and ventricular tachycardia. The real-world acute conversion rate of atrial fibrillation and atrial flutter is higher than that reported in clinical trials. Dofetilide has an acceptable safety profile when initiated (or reloaded) under hospital monitoring and dosed according to creatinine clearance. Dofetilide is well tolerated and a good choice for patients with acceptable renal function and a normal QT interval, especially if atrioventricular nodal blockade needs to be avoided.",
author = "Deborah Wolbrette and Sarah Hussain and Ilir Maraj and Gerald Naccarelli",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1074248418784288",
language = "English (US)",
volume = "24",
pages = "3--10",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - A Quarter of a Century Later

T2 - What is Dofetilide’s Clinical Role Today?

AU - Wolbrette, Deborah

AU - Hussain, Sarah

AU - Maraj, Ilir

AU - Naccarelli, Gerald

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post–myocardial infarction patients and those with heart failure. This is a review of postmarket data, including real-world efficacy and safety in a variety of populations. Dofetilide has been used off-label with success in patients with paroxysmal atrial fibrillation and atrial flutter, as well as atrial tachycardia and ventricular tachycardia. The real-world acute conversion rate of atrial fibrillation and atrial flutter is higher than that reported in clinical trials. Dofetilide has an acceptable safety profile when initiated (or reloaded) under hospital monitoring and dosed according to creatinine clearance. Dofetilide is well tolerated and a good choice for patients with acceptable renal function and a normal QT interval, especially if atrioventricular nodal blockade needs to be avoided.

AB - Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post–myocardial infarction patients and those with heart failure. This is a review of postmarket data, including real-world efficacy and safety in a variety of populations. Dofetilide has been used off-label with success in patients with paroxysmal atrial fibrillation and atrial flutter, as well as atrial tachycardia and ventricular tachycardia. The real-world acute conversion rate of atrial fibrillation and atrial flutter is higher than that reported in clinical trials. Dofetilide has an acceptable safety profile when initiated (or reloaded) under hospital monitoring and dosed according to creatinine clearance. Dofetilide is well tolerated and a good choice for patients with acceptable renal function and a normal QT interval, especially if atrioventricular nodal blockade needs to be avoided.

UR - http://www.scopus.com/inward/record.url?scp=85049694857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049694857&partnerID=8YFLogxK

U2 - 10.1177/1074248418784288

DO - 10.1177/1074248418784288

M3 - Review article

C2 - 29940780

AN - SCOPUS:85049694857

VL - 24

SP - 3

EP - 10

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 1

ER -